乌体林斯联合吡柔比星膀胱灌注预防浅表膀胱癌术后复发疗效观察

目的：比较乌体林斯联合吡柔比星与单独吡柔比星膀胱灌注预防非肌层浸润性膀胱癌电切术后复发的疗效。方法：临床62例非肌层浸润性膀胱癌患者,常规行经尿道膀胱癌电切术,术后随机分为两组,一组给予乌体林斯联合吡柔比星,另一组只给予吡柔比星膀胱灌注,门诊定期复查,持续2年。结果：联合灌注组肿瘤复发率为38.7%,单独灌注组肿瘤复发率为64.5%,差异有统计学意义（P〈0.05）。Ta期肿瘤,联合灌注组的复发率为25.0%,单独灌注组的复发率为58.3%,差异有统计学意义（P〈0.05）。T1期肿瘤,联合灌注组的复发率为47.4%,单独灌注组的复发率为68.4%,差异没有统计学意义（P〉0.05）。结论：对Ta期非肌层浸润性膀胱癌,乌体林斯联合吡柔比星膀胱灌注预防术后复发的疗效优于单纯吡柔比星灌注。

Intravesical Instillation of Mycobacterium Phlei F.U.36 in Combination with Pirarubicin Hydrochloride against Postoperative Recurrence of Superficial Bladder Cancer

OBJECTIVE：To evaluate the clinical efficacy of intravesical instillation of mycobacterium phlei F.U.36 in combination with pirarubicin hydrochloride versus pirarubicin hydrochloride alone against the recurrence of superficial bladder cancer after transuretheral resection （TUR-BT）.METHODS：Sixty-two patients with superficial bladder cancer after undergoing TUR-BT were randomly assigned to receive either intravesical instillation of mycobacterium phlei F.U.36 in combination with pirarubicin hydrochloride or intravesical instillation of pirarubicin hydrochloride alone.Regular follow-up was performed for two years.RESULTS：The total recurrence rate was 38.7% in the combination therapy group as compared with 64.5% in the single therapy group,and the difference was statistically significant （P0.05）.As for stage Ta tumor,the recurrence rate was 25.0% in the combination group as compared with 58.3% in the single therapy group,and the difference was statistically significant （P0.05 ）.Regarding stage T1 tumor,the recurrence rate was 47.4% in the combination group as compared with 68.4% in the single therapy group,the difference was not statistically significant （P0.05）.CONCLUSION：Mycobacterium phlei F.U.36 in combination with pirarubicin hydrochloride has better efficacy than does pirarubicin hydrochloride alone against the recurrence of superficial bladder cancer after TUR-BT.